| Mr Jacob Wayne Moss, MD, JD | |
|
283 N 1st St, Driggs, ID 83422-5109 | |
| (208) 354-2302 | |
| (208) 354-8392 |
| Full Name | Mr Jacob Wayne Moss |
|---|---|
| Gender | Male |
| Speciality | General Practice |
| Experience | 11 Years |
| Location | 283 N 1st St, Driggs, Idaho |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205179751 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Teton Valley Hospital | Driggs, ID | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Teton Valley Health Care Inc | 3870744956 | 29 |
News Archive
By hosting the first national conference on oral and systemic health in Baltimore on Dec. 10, the University of Maryland, Baltimore (UMB) took another major step toward true interprofessional health care education, says Jay A. Perman, MD, president of the University.
In the United States, March is Women's History Month. While it is a time to reflect on the contributions women have made to the fields of politics, art, science, medicine and elsewhere, it is also a time to pay attention to the issues that women today are facing in their daily lives.
The oncologist should be the primary decision maker in some pediatric cancer situations, say researchers at Baylor College of Medicine (BCM) in Houston in an article appearing today in the Journal of Clinical Oncology.
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.
AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer.
› Verified 9 days ago
| Entity Name | Teton Valley Health Care Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013264183 PECOS PAC ID: 3870744956 Enrollment ID: O20121128000587 |
News Archive
By hosting the first national conference on oral and systemic health in Baltimore on Dec. 10, the University of Maryland, Baltimore (UMB) took another major step toward true interprofessional health care education, says Jay A. Perman, MD, president of the University.
In the United States, March is Women's History Month. While it is a time to reflect on the contributions women have made to the fields of politics, art, science, medicine and elsewhere, it is also a time to pay attention to the issues that women today are facing in their daily lives.
The oncologist should be the primary decision maker in some pediatric cancer situations, say researchers at Baylor College of Medicine (BCM) in Houston in an article appearing today in the Journal of Clinical Oncology.
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.
AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer.
› Verified 9 days ago
| Entity Name | Aaa American Healthcare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285979757 PECOS PAC ID: 5294037388 Enrollment ID: O20160106001786 |
News Archive
By hosting the first national conference on oral and systemic health in Baltimore on Dec. 10, the University of Maryland, Baltimore (UMB) took another major step toward true interprofessional health care education, says Jay A. Perman, MD, president of the University.
In the United States, March is Women's History Month. While it is a time to reflect on the contributions women have made to the fields of politics, art, science, medicine and elsewhere, it is also a time to pay attention to the issues that women today are facing in their daily lives.
The oncologist should be the primary decision maker in some pediatric cancer situations, say researchers at Baylor College of Medicine (BCM) in Houston in an article appearing today in the Journal of Clinical Oncology.
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.
AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Jacob Wayne Moss, MD, JD 241 Harvard Ave, Rexburg, ID 83440-2210 Ph: (208) 313-1438 | Mr Jacob Wayne Moss, MD, JD 283 N 1st St, Driggs, ID 83422-5109 Ph: (208) 354-2302 |
News Archive
By hosting the first national conference on oral and systemic health in Baltimore on Dec. 10, the University of Maryland, Baltimore (UMB) took another major step toward true interprofessional health care education, says Jay A. Perman, MD, president of the University.
In the United States, March is Women's History Month. While it is a time to reflect on the contributions women have made to the fields of politics, art, science, medicine and elsewhere, it is also a time to pay attention to the issues that women today are facing in their daily lives.
The oncologist should be the primary decision maker in some pediatric cancer situations, say researchers at Baylor College of Medicine (BCM) in Houston in an article appearing today in the Journal of Clinical Oncology.
Stromedix, Inc., a biotechnology company focused on innovative therapies for fibrosis and organ failure, announced today that it has exclusively licensed the rights to a monoclonal antibody to integrin αvβ5 from the University of California. This compound is the second Stromedix pipeline asset to be sourced from the laboratory of Dean Sheppard, M.D., at University of California, San Francisco.
AEterna Zentaris Inc., a global biopharmaceutical company focused on endocrine therapy and oncology, today announced positive efficacy data from a Phase 2 study with its targeted cytotoxic peptide conjugate, AEZS-108 (formerly AN-152), in patients with platinum-resistant and taxane-pretreated ovarian cancer.
› Verified 9 days ago
Lanie Benson, General Practice Medicare: Not Enrolled in Medicare Practice Location: 460 N 3rd E, Driggs, ID 83422 Phone: 208-821-2141 |